Last reviewed · How we verify
Revelise (GENERIUM, Russia)
Revelise (GENERIUM, Russia) is a Erythropoietin-stimulating agent (ESA) Biologic drug developed by AO GENERIUM. It is currently in Phase 3 development for Anemia associated with chronic kidney disease, Chemotherapy-induced anemia.
Revelise is a recombinant human erythropoietin (EPO) analog that stimulates red blood cell production by binding to erythropoietin receptors on bone marrow progenitor cells.
Revelise is a recombinant human erythropoietin (EPO) analog that stimulates red blood cell production by binding to erythropoietin receptors on bone marrow progenitor cells. Used for Anemia associated with chronic kidney disease, Chemotherapy-induced anemia.
At a glance
| Generic name | Revelise (GENERIUM, Russia) |
|---|---|
| Sponsor | AO GENERIUM |
| Drug class | Erythropoietin-stimulating agent (ESA) |
| Target | Erythropoietin receptor (EPOR) |
| Modality | Biologic |
| Therapeutic area | Hematology/Oncology |
| Phase | Phase 3 |
Mechanism of action
The drug mimics the action of endogenous erythropoietin, a hormone that regulates red blood cell production. By activating EPO receptors on erythroid progenitor cells in the bone marrow, it promotes proliferation and differentiation of these cells, leading to increased hemoglobin and hematocrit levels. This mechanism is used to treat anemia associated with chronic kidney disease, cancer chemotherapy, and other conditions.
Approved indications
- Anemia associated with chronic kidney disease
- Chemotherapy-induced anemia
Common side effects
- Hypertension
- Thromboembolism
- Headache
- Injection site reactions
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Revelise (GENERIUM, Russia) CI brief — competitive landscape report
- Revelise (GENERIUM, Russia) updates RSS · CI watch RSS
- AO GENERIUM portfolio CI
Frequently asked questions about Revelise (GENERIUM, Russia)
What is Revelise (GENERIUM, Russia)?
How does Revelise (GENERIUM, Russia) work?
What is Revelise (GENERIUM, Russia) used for?
Who makes Revelise (GENERIUM, Russia)?
What drug class is Revelise (GENERIUM, Russia) in?
What development phase is Revelise (GENERIUM, Russia) in?
What are the side effects of Revelise (GENERIUM, Russia)?
What does Revelise (GENERIUM, Russia) target?
Related
- Drug class: All Erythropoietin-stimulating agent (ESA) drugs
- Target: All drugs targeting Erythropoietin receptor (EPOR)
- Manufacturer: AO GENERIUM — full pipeline
- Therapeutic area: All drugs in Hematology/Oncology
- Indication: Drugs for Anemia associated with chronic kidney disease
- Indication: Drugs for Chemotherapy-induced anemia
- Compare: Revelise (GENERIUM, Russia) vs similar drugs
- Pricing: Revelise (GENERIUM, Russia) cost, discount & access